Heleen
de Jong
,
Kimberly M.
Bonger
* and
Dennis W. P. M.
Löwik
*
Department of Synthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University Nijmegen, The Netherlands. E-mail: k.bonger@science.ru.nl; d.lowik@science.ru.nl
First published on 26th August 2020
An important hurdle for the intracellular delivery of large cargo is the cellular membrane, which protects the cell from exogenous substances. Cell-penetrating peptides (CPPs) can cross this barrier but their use as drug delivery vehicles is hampered by their lack of cell type specificity. Over the past years, several approaches have been explored to control the activity of CPPs that can be primed for cellular uptake. Since the first report on such activatable CPPs (ACPPs) in 2004, various methods of activation have been developed. Here, we provide an overview of the different ACPPs strategies known to date and summarize the benefits, drawbacks, and future directions.
A promising method for the intracellular delivery of membrane-impermeable therapeutics emerged with the discovery that certain peptides could transfer cargo across the cell membrane. In 1988, two separate research groups reported that human influenza virus (HIV) Tat trans-activator proteins enabled cellular uptake along with the transport of cargo.2,3 Green and Loewenstein also identified the primary sequence of the uptake region of Tat (RKKRRQRRR).2 Since these first reports, many other so-called cell penetrating peptides (CPPs) have been identified including Antennapedia homeoprotein derived Penetratin,4 Arf(1–22) and M918 derived from p14Arf,5,6 and Xentry derived from the hepatitis B virus (Table 1, entries 1–5).7 In addition, several synthetic CPPs have been designed containing polybasic or hydrophobic residues, including polyarginine,8 Pip,9 CADY,10 and others (Table 1, entries 6–8).
Name | Sequence | Source | Ref. | |
---|---|---|---|---|
Natural occurring CPPs | ||||
1 | Tat | RKKRRQRRR | HIV | 2 and 3 |
2 | Penetratin | RQIKIWFQNRRMKWKK | Antennapedia | 4 |
3 | Arf(1–22) | MVRRFLVTLRIRRACGPPRVRV | p14Arf | 5 |
4 | M918 | MVTVLFRRLRIRRACGPPRVRV | p14Arf | 6 |
5 | Xentry | LCLRPVG | Hepatitis B virus | 7 |
Synthetic CPPs | ||||
6 | PolyArg | Rn (n > 6) | NA | 8 |
7 | Pip | (RXR)3IKILFQNRRMKWKK | NA | 9 |
8 | CADY | GLWRALWRLLRSLWRLLWKA | NA | 10 |
The cellular uptake mechanisms of CPPs have been extensively studied, but are still poorly understood as different CPPs seem to enter cells through different pathways.11,12 Mechanisms of uptake can be classified in two categories: energy independent direct penetration and energy dependent endocytosis (Fig. 1). Direct penetration occurs in cases when a high concentration of peptide is available and involves a tight interaction between the CPPs and cell membrane. Direct cell penetration mechanisms include (1) pore formation, where the CPPs insert themselves in the membrane; (2) the carpet model, where CPPs position on the membrane as a carpet, thereby increasing membrane fluidity and passage of the CPPs; and (3) inverted micelle formation, where the phospholipid bilayer encapsulates the peptide by formation of inverted micelles. However, CPPs, especially those that carry cargo, internalize mainly through endocytic pathways.13 These include micropinocytosis, clathrin- or caveolin-mediated endocytosis, and clathrin/caveolin independent endocytosis.14 The path taken depends on the size and physicochemical properties of the cargo as well as the nature of the CPP and the target cell.15 For more detailed information on the uptake mechanisms of CPPs and the contributing factors we refer to some recent reviews on this topic.12,16
![]() | ||
Fig. 1 Schematic summary of various mechanisms of cellular uptake of cationic cell-penetrating peptides (CPPs) via endocytic pathways or direct penetration. |
Even though CPPs are potentially promising drug delivery vehicles, several issues hamper their use in practice. These include (1) their lack of cell type specificity resulting in uncontrolled uptake and potential adverse effects,17 (2) their toxicity at high concentrations, which is associated with membrane perturbation18 and (3) their fast blood clearance as was shown by a study where only 1% of the injected dose of ten different CPPs remained at the target site after 4 h in tumour bearing mice.17
To overcome these challenges, much research is focussed over the last years to control CPPs and to activate them only at the target site by use of an external trigger (Fig. 2). The Tsien group first described such so-called Activatable CPPs (ACPPs) in 2004 where they fused a polycationic CPP to an inhibiting polyanionic domain via a protease cleavable linker.19 Since then, numerous advances in the development of ACPPs and their triggers have been reported. In this review, we provide an overview of the strategies in the design of ACPPs since their discovery more than 15 years ago.
![]() | ||
Fig. 2 Dormant cell-penetrating peptides (CPPs) cannot enter cells. Upon triggering they are activated and can be taken up by cells. |
CPP | Trigger | Ref. | ||||
---|---|---|---|---|---|---|
Enzyme sensitive linkers | ||||||
1 | PLGLAG | r9 | e6,8 | Cy5 | MMP-2 and -9 | 19 and 21 |
R9 | E8 | PpIX | 23 | |||
R9 | E9 | Dox | 24 | |||
Poly(M-block-K) | PEG | Dox | 25 | |||
2 | PVGLIG | R9 | (EGG)3 | CsA-LMNC | MMP-9 | 26 |
3 | PGFK | Tat | E6 | Dox | Cathepsin B | 28 |
4 | HSSKYQ | R8 | (DGG)4 | PLK-1 siRNA | PSA | 29 |
5 | RLQLK(Ac)L | r9 | e9 | Cy5 | NE | 32 |
6 | DPRSFL | r9 | e8 | Cy5 Rhodamine | Thrombin | 33 |
pH sensitive linkers | ||||||
7 |
![]() |
R8 | (ehG)4 | PLK-1 siRNA | pH < 6.8 | 37 |
ROS sensitive linkers | ||||||
8 |
![]() |
R9 | E9 | FITC Cy5 | H2O2 | 43 |
Light sensitive linkers | ||||||
9 |
![]() |
Tat | PEG | Liposomes loaded with Atto655 | λ = 254 nm, 2 min | 47 |
10 |
![]() |
R7 | E7 | FITC CPT | λ = 365 nm, 10 min | 48 |
11 |
![]() |
Penetratin | E4R4 | EGFR siRNA | λ = 740 nm, 30 min and pH < 6.4 | 53 |
12 |
![]() |
R7 | E7 | QDs | Two-photon, λ = 740 nm, 3 h | 48 |
Using a similar ACPP construct with the MMP-sensitive linker, the Zhang group delivered a protoporphyrin photosensitizer to fibrosarcoma cells in vivo.23 Imaging experiments demonstrated efficient localization to tumours and a decrease in tumour size upon a 12-day treatment of injections once every three days. Alternatively, the group of Cao delivered doxorubicin (DOX) to human breast adeno-carcinoma cells, but not to MMP deficient human mammary endothelial cells, by coating DOX-loaded nanoparticles with MMP-triggered ACPPs.24 The Kim group combined MMP-responsiveness with reactive oxygen species (ROS) triggers to additionally advance the control of drug delivery.25 In this case, micelles were coated with ACPPs based on (poly(L-methionine-block-L-lysine)–PLGLAG–PEG) and loaded with DOX or IR-760 dye. MMP-assisted PLGLAG cleavage activated the polylysine-based ACPP to facilitate cellular uptake after which ROS oxidized the methionine thioether moieties to hydrophilic sulfoxide groups thereby destabilizing the micelle structures. High accumulation in tumours and a long retention time were observed, as well as efficient ROS triggered cargo release.25
Chen and coworkers coated a cyclosporine A loaded nanocarrier with an ACPP connected via an alternative MMP sensitive linker (PVGLIG) and studied the localization in controlled cortical impact injury mice (Table 2, entry 2).26 The structures crossed the blood brain barrier and internalized into primary astrocytes and neurons at the lesion site. Cyclosporine A inhibits the opening of the mitochondrial permeability transition pore thereby preventing apoptosis. Less cell death was observed around the lesion site in mice treated with the cyclosporine A-loaded and ACPP-coated nanocarriers compared to the cyclosporine A treated controls.
Besides MMPs, a cathepsin B cleavable sequence, PGFK, has been used to connect a polyanionic inhibitor to a Tat derived CPP that was conjugated to mesoporus silica quantum dot nanocarriers loaded with DOX (Table 2, entry 3).27,28 In the presence of endogenous cathepsin B levels, DOX was released and transported selectively to the nuclei of human adenocarcinoma cells while uptake was drastically decreased in the absence of cathepsin B.
Xiang and coworkers used the prostate-specific antigen (PSA), which is overexpressed in prostate cancer, as trigger to specifically deliver siRNA against the polo-like kinase 1 (PLK-1) transcript. PLK-1 induces apoptosis in cancer cells when depleted.29,30 The authors coated siRNA loaded liposomes with ACPPs containing a PSA-responsive HSSKYQ linker between a polycationic CPP and a polyanionic peptide inhibitor (Table 2, entry 4). Flow cytometry and imaging studies indicated increased uptake in PSA rich human prostate cancer 22Rv1 cells compared to PSA deficient PC-3 cells. Moreover, PLK-1 expression was decreased in the prostate cancer cell line treated with the liposomes, but not in the untreated control. In these experiments, increased apoptosis accompanied PLK-1 downregulation. In vivo studies with 22Rv1 xenograft tumours showed increased tumour accumulation for ACPP coated liposomes, compared to polycationic CPP coated liposomes.
Neutrophil elastase is highly abundant in several cancers, such as human breast and lung cancer.31 The Tsien group included a neutrophil elastase sensitive RLQLK(Ac)L sequence in an ACPP design to visualize tumours with a Cy5 dye (Table 2, entry 5).32 The acetylated lysine improved specificity for the neutrophil elastase over other endogenously expressed elastases. Injection of ACPPs in nude mice with human breast cancer xenografts visualized the tumour 6 h after injection, while the structure was not observed in mice treated with control structures where the inhibiting domain was linked via a non-cleavable D-amino acid based sequence (rlqlkl).
The Tsien group further extended the ACPP concept using a thrombin-sensitive DPRSFL linker between a fluorescently labelled cationic CPP and an anionic inhibitory domain for imaging purposes (Table 2, entry 6).33 Thrombin is active in blood coagulation and abundant in atherosclerotic plaques, which narrow arteries.34,35 Gel electrophoresis showed that purified thrombin could cleave the ACPP in vitro. The ACPP was injected in mice with induced atherosclerosis and 6 h after injection, a positive fluorescence correlation was observed with plaque burden for the ACPP but not for non-cleavable controls. Fluorescence distribution was also increased in slices of human atheromas that were treated with the ACPP ex vivo, but not for those treated with the non-cleavable control.
Hydrazones rapidly hydrolyse to a ketone and a hydrazine under acidic conditions and were included in the design of acid-sensitive ACPPs. Here, Xiang and coworkers coated PLK-1 siRNA loaded liposomes with hydrazone based ACPPs, where the hydrazone linked a polyanionic inhibiting domain to the polycationic CPP (Table 2, entry 7).37 Lowering the pH from 7.4 to 6.8 resulted in loss of the inhibitory domain, a decrease in PLK-1 mRNA levels, reduced PLK-1 protein expression and a significant increase in apoptosis, suggesting successful release of the siRNA.
The use of high energy UV light to activate ACPPs is less desirable for use in vivo as it has low penetration depth and damages tissue.49,50 Light triggered ACPPs based on low energy near-infrared (NIR) light have also been explored.51 NIR can cleave NIR-sensitive PCLs at the target site or UV-sensitive PCLs using two-photon excitation. In two-photon excitation, short light pulses of low-energy photons reach the target site quasi-simultaneously to generate enough energy to give rise to bond cleavage.52 The Mei group obtained a PCL by inclusion of a trimethyl lock, which increases reactivity through a favourable ring closing reaction.53,54 This PCL was used to connect a penetratin derived CPPs with a pH-sensitive inhibitory domain and these structures were coated onto siRNA-loaded nanocarriers (Table 2, entry 11). Cellular imaging studies in human breast adenocarcinoma cells indicated that both two-photon irradiation (λ = 740 nm) and a pH change were required for internalization, which led to reduced levels of the corresponding mRNA. Furthermore, ACCPs based on an ester bound o-nitrobenzyl PCL could be activated by two photon light (λ = 740 nm, 16 mW), which resulted in successful uptake in HeLa cells as evidenced by cellular imaging (Table 2, entry 12).48
Number of R groups | CPP | Cargo | Trigger | Ref. | ||
---|---|---|---|---|---|---|
Enzyme sensitive side chain modifications | ||||||
1 |
![]() |
1 or 2 | Tat | FITC | Aminopeptidase N dipeptidyl peptidase IV | 55 |
2 |
![]() |
2 | M918 | Luc PNA | Bacterial azoreductase | 57 |
pH sensitive side chain modifications | ||||||
3 |
![]() |
3 | Tat | Dox | pH 5.0 | 58 |
4 |
![]() |
6 | CR8G3PK6 | Dox | pH 6.8 | 59 |
Light sensitive side chain modifications | ||||||
5 |
![]() |
3 | Pen | (klaklak)2 | λ = 365 nm, 6 W, 10 min | 60 |
6 |
![]() |
3 | Pen | VB | λ = 740 nm, 30 min, 3.48 × 1012 photons s−1 | 61 |
Leroux et al. explored an activation strategy using bacterial azoreductases, which are found in human colon mucosa and cleave azobenzene structures.56 Their synthetic CPPs were inactivated by conjugating PEG fragments to the side chains via an azobenzene moiety (Table 3, entry 2).57 As a proof of principle, a silencing peptide nucleic acid (PNA) specific for the firefly luciferase gene was conjugated to the C-terminus of the ACPP to monitor cell entry in luciferase-expressing colon adenocarcinoma cells. Incubation of the cells for two days resulted in azobenzene cleavage and 1,6-elimination followed by cell uptake of the CPP–PNA conjugate, as evidenced by a 40% decrease in luciferase activity compared to control cells.
Using a similar approach, Cheng et al. conjugated 2,3-dimethyl-maleic acid (DMA) to the lysine residues of a cationic CPP peptide (Table 3, entry 4).59 The DMA-linked lysine residues underwent electrostatic interactions with the arginine residues in the chain, thereby inactivating the ACPP. The labile amides hydrolysed at pH 6.8 and the DOX-linked ACPPs were efficiently taken up at this pH. Furthermore, they demonstrated that nonspecific cellular toxicity decreased, while repression of tumour growth resembled that of free DOX.
Similarly, the Mei group conjugated o-nitrobenzyl photocages to the lysine residues of a Penetratin derived CPP and coated these onto liposomes loaded with anticancer agent Vinorelbine (VB, Table 3, entry 6).61 Two-photon NIR light activation (λ = 740 nm, 30 min) of the ACPP-coated liposomes resulted in uptake into human fibrosarcoma cells accompanied by a decreased viability and indicating that cargo could be delivered effectively.
Premise | CPP | Inhibiting factor | Cargo | Trigger | Ref. | |
---|---|---|---|---|---|---|
pH sensitive conformational changes | ||||||
1 |
![]() |
Tat | PEG | DOX loaded micelle | pH drop | 63 |
2 |
![]() |
TH | H side chain charge | CPT | pH drop | 64 |
LH | CPT | 66 | ||||
TH | PTX probe | 65 | ||||
3 |
![]() |
K97 | SC modi-fications with imi-dazole or carboxylic acids | pH drop to 6.0 | 67 | |
Light sensitive conformational changes | ||||||
4 |
![]() |
LK | trans-Ab | Tamra | 365 nm, 5 min, 8 mW cm−2 | 68 |
5 |
![]() |
R9 | E9 | RhoB | λ = 488, 1–1.5 μW, ∼60 ms μm−2 | 69 |
6 |
![]() |
RRF-yAhxP-FRR | Circular structure | FITC | λ = 590 nm | 70 |
Both the Wang group and He group developed ACPPs by exchanging all lysine residues in two lysine-rich CPPs for histidines, creating respectively TH (AGYLLGHINLHHLAHLXHHIL, with X = 2-aminoisobutyric acid)64,65 and LH (LHHLLHHLHHLLHH, Table 4, entry 2).66 At physiological pH, neither peptide is able to enter cells, unlike their lysine rich counterparts (TK and LK, respectively). Acidification to pH 6 protonated the histidine residues and induced cellular uptake. With this system, the Wang group delivered anticancer drug camptothecin intracellularly with both peptides – TH for HeLa cells and LH for human breast adenocarcinoma cells.64,66 The He group coated TH onto liposomes loaded with either the drug paclitaxel or IR-probes.65 Paclitaxel was delivered to tumorigenic tissue in vitro, as demonstrated by flow cytometry and cellular imaging, while NIR imaging showed in vivo delivery of IR-probes to the tumour sites.
The Kim group harnessed α-helical conformational requirements in their ACPP design. They introduced imidazole and carboxylic acid groups onto lysine residues to ensure pH-dependent conformational control of a synthetic, polylysine-based CPP (Table 4, entry 3).67 At physiological pH, the charge distribution created an inactive, tightened helix, while in a slightly acidic environment (pH 6) the partial protonation gave rise to an intact helical structure that could enter cells. When the pH dropped below 4, however, additional protonation stretched the helix further through strong intramolecular electrostatic repulsion that led to inhibition of uptake. They demonstrated the potential of the approach by showing that the ACPPs were taken up in human lung carcinoma cells at pH 6, but not at pH 7.4.
The Möller group placed the azobenzene linker in between an oligo-arginine and an oligo-glutamate domain to enable the reversible activation of the CPP using light. The authors included a fluorescent rhodamine B (RhoB) label for visualization and evaluation of the uptake of the construct (RhoB-E9-Ab-R9, Table 4, entry 5).69 Irradiation of the azobenzene with UV light to the cis-conformation (λ = 366 nm, 20 min) resulted in a parallel configuration of the two peptide chains and inactivation of the CPP. Repeated irradiation with longer wavelength laser light (λ = 488, 1–1.5 μW, ∼60 ms μm−2) recovered a trans-conformation and restoring CPP activity. With this construct, high spatial control could be achieved as cellular uptake was only observed in 488 nm irradiated areas without inducing cellular toxicity as evidenced by confocal microscopy and quantified by flow cytometry.
Photoswitches have also been combined with benign red light activation. The Ulrich group designed circular ACPPs consisting of a peptide fragment of 9 to 14 residues, with a charge between +4 and +10, and a photoswitchable diarylethene (DAE) group (Table 4, entry 6).70 DAE is a rigid structure that becomes flexible upon irradiation with visible light (λ = 590 nm), while irradiation with UV-light brings the DAE to its rigid form. The rigid DAE imposed a non-optimal structure for the circular ACPP thereby preventing it from entering the cell. Irradiation with visible light induced a conformational change that enabled cellular penetration, which increased 1.6 to 6.5 fold depending on the peptide sequence.
As an alternative conjugation strategy, the Löwik group explored the construction of active CPPs using leucine zippers.72 Leucine zippers are α-helical structural motifs found in proteins that dimerise when in close contact.73 For the design of these heterodimeric zipper-based ACPPs, monomeric zippers were conjugated to either a tetraarginine or a fluorescently labelled tetraarginine. Assembly of the peptide zippers resulted in the formation of a semi-linear octaarginine chain and subsequent uptake in HeLa cells (Table 5, entry 2). The authors further showed that using these zipper constructs, not only low molecular weight FITC but also superfolder green fluorescent protein (27 kDa) could be transported into the cells.
In a follow up study, the authors assembled ACPPs using bioorthogonal chemistry. This chemistry is widely used for a variety of bioconjugation applications in vitro and recent developments of the bioorthogonal reactants has also made this chemistry applicable in vivo.74 In this case, tetraarginines were conjugated to various bioorthogonal handles that could be used for an in situ conjugation via the inverse electron-demand Diels–Alder reaction with tetrazines, one of the fastest bioconjugation reactions known to date (Table 5, entry 3).75 The authors modified one tetraarginine half with a fluorophore and a tetrazine (Tz) and another half with a bicyclo[6.1.0]nonyne (BCN) or a trans-cyclooctene (TCO) moiety. Upon 30 minutes of incubation of the two halves, a level of cellular uptake was observed comparable to that of pre-conjugated CPP halves or to the native octaarginine CPP as evidenced by confocal scanning laser microscopy and flow cytometry. Moreover, using a slightly longer incubation time (90 minutes) and a moderately increased peptide concentration (10 μM versus 5 μM), the BCN–Tz delivery system was successfully used to deliver the 66 kDa human serum albumin protein into HeLa cells.
The Gianneschi group described activation of cellular uptake through polymerization of peptides into high density bushes.82 They attached either one or two arginine or lysine residues to a short peptide sequence without any positively charged amino acids (GSGSG) and that lacks cell penetrating properties. The peptides were equipped with norendimide moieties, and the resulting alkene monomers were polymerized with oligoethelyne glycol to form block copolymers. Peptide oligomers with a degree of polymerization (DP) of 60 – resulting in 60 or 120 positive charges depending on addition of one or two positive amino acids – showed cellular uptake in HeLa cells (Table 5, entry 5). This strategy was expanded to the non-internalizing, lysine rich, apoptotic peptide KLAK. When this peptide was conjugated to the polymer (DP = 5, 10, 15), again, cellular uptake was observed through flow cytometry while the apoptotic properties of KLAK remained intact in a dose-dependent manner. It should be noted, however, that the structures were polymerized before administration and could not be activated on site. To evolve this strategy to its full potential with respect to ACPP design, the possibility of targeted on site polymerization is essential. Such a strategy may provide a potent approach for transportation of therapeutic peptides across the cell membrane.
CPPs can be temporarily inactivated by introducing interacting inhibitory domains or, when bulky groups are undesired, smaller side chain modifications on, for example, lysine residues to mask CPP activity. Masking groups can be removed by local triggers such as enzymes or changes in pH as well as external triggers such as light. While several approaches are summarized in this review, the list of sensitive linkers and possible triggers is far from exhausted. Besides unidirectional activation through removal of inhibitory moieties, reversible activation has also been achieved by controlling the peptide conformation.
Unfortunately, the triggers used to activate CPPs are not that binary in vivo. Enzymes that are overexpressed in diseased tissue may still be present in lower amounts in healthy tissue, and gradient pH values are often observed between tissues. CPP activation by irradiation with light is beneficial to create temporal and special control, but is challenged by the poor tissue penetration depth as well as the potential cellular toxicity induced by the harmful wavelengths. These unintended triggers may create off-target effects and should be accounted for. Nevertheless, some of the research covered in this review demonstrated the benefit of using ACPPs in vivo.
Activation of CPPs by conjugating two inactive peptide halves does not require an environmental trigger. Spatial control of CPP activity can be achieved by including a targeting entity on one of the peptide halves, such as an antibody or localizing small molecule. Here, the targeted fragments localize to the target site of interest, after which their counterparts interact and prime them for cellular uptake. Using bioorthogonal chemistry, such a pre-targeting approach has already been used to increase, for example, the radiolabelling specificity in vivo.84 Successful in vivo conjugations rely on the availability of highly stable reactants and reactions with exceptional high rate constants as the reactant concentration in vivo are low.
CPPs have entered clinical trials for treatments of several dysfunctions including hearing loss,85 coronary artery disease,86 macular degeneration,87 solid tumours,88 central nervous tumours,89 scar prevention,90 heart attack,91 Duchenne muscular dystrophy,92 and ocular inflammation.93 However, to date, none have been approved for therapeutic use. CPP application in the clinic is challenged by the limited bio-distribution and accumulation of the structures in liver or kidney.17 In addition, the half-life of the structures varied from 1.2 to >72 hours, where short lived CPPs generally contained cationic residues likely making them more susceptible for proteolytic cleavage. Adopting ACPP strategies as described in here may improve the stability and bio-distribution of the constructs and therefor also possible clinical translation.
To the best of our knowledge, one ACPP has been tested in a phase 1 clinical study and used for imaging purposes.94 This ACPP was designed to visualize tumours during surgical procedures and resembled the ACPP designed by the Tsien group, containing an inhibitory domain and a protease-sensitive linker.19,95,96 In this construct, the CPP as well as the inhibitory domain each carried a fluorophore thereby inducing FRET. Proteolytic cleavage in tumorigenic tissue disabled FRET resulting in a measurable change of fluorescence intensity. The ACPP was administered via intravenous infusion for 30 minutes, 2 to 20 h before the surgery and allowed the discrimination between tumour-positive and tumour-negative tissue with limited adverse events. This positive application and the increased specificity of ACPPs over native, non-activatable CPPs greatly improves their possible use for other applications in vivo. Keeping in mind the variety of ACPPs and their activation triggers, we foresee promising clinical potential for the local cellular delivery of a variety of therapeutics using these structures.
This journal is © The Royal Society of Chemistry 2020 |